Used as a key intermediate in the synthesis of quinazoline-based pharmaceuticals, particularly in the development of tyrosine kinase inhibitors. It serves as a building block for compounds targeting cancer therapies, especially in the design of epidermal growth factor receptor (EGFR) inhibitors. The benzyl and methoxy substituents allow selective modifications, enabling optimization of biological activity and pharmacokinetic properties in drug candidates. Its structure supports the formation of hydrogen bonds and π-π interactions, enhancing binding affinity to target enzymes. Commonly employed in medicinal chemistry research for generating novel antitumor agents.